Showing 7851-7860 of 18164 results for "".
Pediatric Metabolic Syndrome
https://reachmd.com/programs/lipid-luminations/pediatric-metabolic-syndrome/4545/A series of well-established risk factors define the metabolic syndrome in adults. The situation is less clear for our younger patients, as they typically do not develop cardiovascular disease or experience cardiac events. The key for kids, it seems, is to determine their risk for disease in adulthoNeural Network Models of Depression
https://reachmd.com/programs/clinicians-roundtable/neural-network-models-of-depression/3837/Dr. Helen Mayberg, professor of psychiatry and neurology at Emory University School of Medicine, joins host Dr. Cathleen Margolin to discuss neural network models of depression. Sharing more than two decades of work in this area, Dr. Mayberg explains how models of mood regulation have led to the devIs there a critical window to begin Hormone Replacement Therapy? Does it really exist?
https://reachmd.com/programs/advances-in-womens-health/is-there-a-critical-window-to-begin-hormone-replacement-therapy-does-it-really-exist/3162/During the 1990's multiple studies suggested hormone replacement therapy would decrease heart disease in women and prolong life. Many doctors encouraged their patients to take estrogen even if they didn't have menopausal symptoms. Dr. Veronica Ravnikar discusses optimizing cardiovascular and cognideCode MI: Another Tool to Assess Patient's MI Risk
https://reachmd.com/programs/clinicians-roundtable/decode-mi-another-tool-to-assess-patients-mi-risk/3291/Are we already able to assess our patients accurately for MI risk factors or is there another test that could provide more accuracy? Our guest today, Dr. Jeffrey Gulcher, chief scientific officer and co-founder of deCode Genetics tells host, Dr. Larry Kaskel about deCode MI. Learn how toRefining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
https://reachmd.com/programs/project-oncology/endorisk-2-preoperative-stratification-endometrial-cancer/39931/Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
https://reachmd.com/programs/project-oncology/relapsed-refractory-dlbcl-treatments/39971/Combination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
https://reachmd.com/programs/dermconsult/combination-therapy-for-plaque-psoriasis-a-reappraisal-of-cyclosporine-and-acitretin/32813/Therapeutic Approaches in Pediatric Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37158/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, explains how to adjust a therapeutic approach to pediatric atopic dermatitis, particularly when considering long-term use of topical steroids or calcinMake Filler Great Again
https://modernaesthetics.com/ma-issues-index/2025-mar-apr/make-filler-great-again-restoring-balance-function-and-trust/36063/Restoring balance, function, and trustDevelopments in Duchenne Muscular Dystrophy Care: Examining the Options
https://reachmd.com/programs/neurofrontiers/developments-in-duchenne-muscular-dystrophy-care-examining-the-options/32357/Advancements in gene therapies have expanded the treatment landscape for Duchenne muscular dystrophy. Read about the benefits and drawbacks of each approach.